Philippe Lagalle, President of CYCLHAD, said: “The delivery of the first proton therapy treatments is a great achievement for the development of cancer care in France. We are pleased to collaborate with IBA, the global leader in proton therapy, which we believe has the required experience to develop the future of this unique technology. The medical need for proton therapy currently exceeds the availability in France, particularly for the treatment of cancers for which it is important to preserve the healthy surrounding tissues and organs. These indications include eye, brain, spinal cord and pediatric cancers. In the next phase of development of this project, we are very pleased to collaborate with IBA and industrial partners to develop a carbon ion accelerator. With this, CYCLHAD plans to create a research center in Caen, which is dedicated to hadron therapy and related technologies.”


About Proteus®ONE

Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, and easier to install and operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide.

*Proteus®ONE is the brand name of a configuration of the Proteus®235.


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).


About CYCLHAD
The operating company CYCLHAD has been created in 2010 in order to finance the hadron therapy project (proton therapy center, carbon solution development as a second step and the building and all related equipment) in Caen, France. IBA has recently invested €1.5 million as part of a capital increase of CYCLHAD and thereby becomes a 33.3% shareholder of the company, alongside with local associations and private investors, mobilized by the Basse-Normandie region.

Back to HCB News

Rad Oncology Homepage